The administration of positive allosteric modulators of α7nAChR (CCMI and PNU-120596), in combination with currently approved anti-AD drugs, to scopolamine-induced memory deficits in rats was evaluated, and it was found that the combined administration of positive allosteric modulators and acetylcholinesterase inhibitors (donepezil) or NMDAR antagonists (memantine) improved performance on the novel object-recognition test (NORT), reversing the scopolamine-induced deficit [339]. The gene discussed is CHRNA7; the disease is Alzheimer disease.